1. Home
  2. NBIX

NBIX

Neurocrine Biosciences Inc.

Logo Neurocrine Biosciences Inc.

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

as 04-12-2024 4:00pm EST

$
-
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.

Founded: 1992 Country:
United States
United States
Employees: N/A City: SAN DIEGO
Market Cap: 13.7B IPO Year: 1996
Target Price: $140.81 AVG Volume (30 days): 885.2K
Analyst Decision: Buy Number of Analysts: 21
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: 2.47 EPS Growth: 58.33
52 Week Low/High: $89.04 - $148.37 Next Earning Date: 05-01-2024
Revenue: $1,887,100,000 Revenue Growth: 26.76%
Revenue Growth (this year): 19.71% Revenue Growth (next year): 16.25%

Share on Social Networks: